THAP7 promotes cell proliferation by regulating the G1/S phase transition via epigenetically silencing p21 in lung adenocarcinoma. 2019

Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, People's Republic of China.

OBJECTIVE Lung adenocarcinoma (LUAD) is one of the most common cancers worldwide. The THanatos-Associated Proteins (THAP) family plays an essential role in multiple cancers. However, the role of THAP7 in cancers has remained elusive. METHODS THAP7 expression status in LUAD tissues was analysed by using the Oncomine database and qRT-PCR, and its expression level in LUAD cell lines was detected by qRT-PCR and Western blotting. The role of THAP7 in LUAD cells was determined by proliferation, colony formation, and cell cycle analyses. In vivo role of THAP7 was studied on xenograft models. Luciferase reporter assays and chromatin immunoprecipitation (ChIP) were used to determine the activity and acetylation of the p21 promoter. RESULTS THAP7 expression was increased in LUAD tissues and cell lines. Moreover, the high expression of THAP7 was correlated with poor prognosis. The overexpression of THAP7 accelerated the G1/S phase transition and promoted tumour growth both in vitro and in vivo. A mechanistic study revealed that THAP7 reduced the acetylation of histone H3 on the p21 promoter to suppress p21 transcription. CONCLUSIONS For the first time, we demonstrated the function of THAP7 in LUAD, and our findings suggested that THAP7 may be a potential molecular therapy target in LUAD.

UI MeSH Term Description Entries

Related Publications

Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
October 2010, Cell cycle (Georgetown, Tex.),
Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
May 2018, Gene,
Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
January 2011, The Prostate,
Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
November 2019, Pathology, research and practice,
Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
June 2013, International journal of molecular medicine,
Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
May 2012, International journal of molecular medicine,
Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
January 2016, Oncology research,
Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
January 2019, Technology in cancer research & treatment,
Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
October 2017, Cell death & disease,
Cai-Ping Chen, and Yi Sang, and Lijuan Liu, and Zhi-Qi Feng, and Zibin Liang, and Xiaofeng Pei
May 2020, Cell death & disease,
Copied contents to your clipboard!